Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.
about
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration.Evaluation of intravenous voriconazole in patients with compromised renal functionEvaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapyA pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia.Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patientsPractice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.Treatment of invasive candidiasis in the elderly: a reviewThe effects of methylphenidate on cognitive control in active methamphetamine dependence using functional magnetic resonance imaging.Update on the optimal use of voriconazole for invasive fungal infections.Invasive aspergillosis in the intensive care unit.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Continuous renal replacement therapy for safe and adequate voriconazole intravenous treatment: enough reason to be confident?Effective treatment of invasive Aspergillus fumigatus infection using combinations of topical and systemic antifungals in a severely burned patient.Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations.A case of Phaeohyphomycosis caused by Corynespora cassiicola infection
P2860
Q33654022-DF5317BB-B481-4333-96FE-64D5D7687508Q33876525-806BB884-75FC-4311-ACC3-7063738FDDD1Q34548752-75C8166C-1E14-4F52-86AD-171874B49AE9Q35114591-89A8CF42-E193-4C02-92AA-7036BD28222CQ35617669-B1225485-3A7D-4B7E-AB78-06CA0F8D919FQ36018898-153CB16F-9EC1-40BC-A54A-AEC2E0737734Q36087577-327D3273-4AA8-4471-A7A5-2B0E927BF151Q36927577-14768CD1-BA57-4812-9586-9375F671FB80Q37170218-E4AFDBC1-50DC-4016-937D-453D0D8A7245Q37620947-267C6FE9-307F-452F-93E1-F41CD6632659Q37892901-64C587C9-A536-4090-8832-32B7671CB11FQ38066616-4AE67E1A-7703-47E4-8322-0653F11E819CQ38681635-7D610B29-2B92-4288-9656-C260CAD5E95AQ38775809-1EE4EDE3-E5AC-45A8-9AB0-16C89F951EE3Q41175527-7FF5FA62-70E2-400B-8135-85BD91B37B2DQ42201729-DAFB9318-ADEC-48EA-A4F2-51A0B5A4B4B5Q43236771-4A4075AC-29F7-4268-A192-B30F3D1DF56DQ47697145-0547224E-C155-4971-B54D-8697108B8992Q58782027-6646E1F7-9A95-490F-A417-C3360148CA36
P2860
Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Accumulation of the solvent ve ...... der renal replacement therapy.
@ast
Accumulation of the solvent ve ...... der renal replacement therapy.
@en
Accumulation of the solvent ve ...... der renal replacement therapy.
@nl
type
label
Accumulation of the solvent ve ...... der renal replacement therapy.
@ast
Accumulation of the solvent ve ...... der renal replacement therapy.
@en
Accumulation of the solvent ve ...... der renal replacement therapy.
@nl
prefLabel
Accumulation of the solvent ve ...... der renal replacement therapy.
@ast
Accumulation of the solvent ve ...... der renal replacement therapy.
@en
Accumulation of the solvent ve ...... der renal replacement therapy.
@nl
P2860
P356
P1476
Accumulation of the solvent ve ...... der renal replacement therapy.
@en
P2093
Ludwig S Weilemann
Marc A von Mach
P2860
P2888
P356
10.1186/1472-6904-6-6
P577
2006-09-18T00:00:00Z
P5875
P6179
1021343942